Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222169 | 0.90 | SIRT1 (0.52) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| Tert-Butyl Formate SCHEMBL27735338 | 0.89 | SIRT1 (0.56) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL221866 | 0.87 | SIRT1 (0.50) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL3503103 | 0.86 | SIRT1 (0.49) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL4695257 | 0.84 | SIRT1 (0.55) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL13660063 | 0.82 | SIRT1 (0.71) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL12167509 | 0.80 | SIRT1 (0.87) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2624783 | 0.79 | SIRT1 (1.00) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL11987212 | 0.78 | SIRT1 (0.42) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL220889 | 0.78 | SIRT1 (0.47) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2993236-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | Glaxosmithkline LLC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20130102009-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | GLAXOSMITHKLINE LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130102009-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | GLAXOSMITHKLINE LLC | 2013-04-25 | — | — | US | disclosed |
| WO-2011130595-A2 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| EP-1910384-A1 | IMIDAZO [2,1-B]THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102009-A1 | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS | SIRT1, SIRT7, SIRT2 | SIRT1 1/4885CHRM2 3573/4885ADRA2A 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.